PLAUR and neoplasm: Additionally, radiotracer uptake has been noted in both local tumour lesions and metastatic lesions.199 In the [68Ga]Ga-NOTA-AE105 PET/CT phase II clinical trial of 96 patients with neuroendocrine neoplasms (NENs), the hazard ratio for progression-free survival and OS with a high uPAR expression level was 1.19–5.88.